NCT02190058已完成1 期
A PHASE I, DOUBLE-BLIND, RANDOMISED, PLACEBO-CONTROLLED, MULTIPLE-DOSE STUDY TO ASSESS SAFETY, TOLERABILITY AND PHARMACOKINETICS OF DS-1971A IN HEALTHY MALE SUBJECTS
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 1
- 主要终点
- adverse events
研究概览
简要总结
This is a randomised, double-blind, placebo-controlled multiple dose study designed to explore the safety, tolerability and PK of DS-1971a following oral administration over 14 days to healthy male subjects.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Basic Science
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 55 Years（Adult）
- 性别
- Male
- 接受健康志愿者
- 是
入选标准
- •Healthy male subjects aged 18-55 years.
- •A body mass index (BMI) in the range 18-30 kg/m2, inclusive, and weighing between 50 and 100 kg at screening.
- •Willing to comply with all study restrictions, including the use of contraception, concomitant medication, and dietary and lifestyle restrictions.
- •Sufficient intelligence to understand the nature of the study and any hazards of participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with requirements of, the entire study.
- •Have given written consent to participate in the study after reading the ICF, and after having the opportunity to discuss the study with the Investigator or his delegate.
- •Have given written consent to have his data entered into The Over-volunteering Prevention System.
排除标准
- •Clinically relevant abnormal history, physical findings, ECG findings, or laboratory values that could interfere with the objectives of the study or compromise the safety of the subject.
- •Presence or history of acute or chronic illness, including (but not limited to) liver or kidney disease, hypertension, seizures, or any known impairment of endocrine, or other specific body-organ dysfunction.
- •History of serious reaction to any medicine.
- •Presence or history of malignant disease.
- •Acute or chronic infectious disease, including human immunodeficiency virus (HIV), hepatitis B virus (HBV) or C virus (HCV) infection.
- •Surgery (eg stomach bypass) or medical condition that might affect how the body handles or absorbs medicines.
- •Significant illness within 4 weeks before the first dose of study medication.
- •Participation in another clinical study of a new chemical entity or a prescription medicine within the previous 3 months, or unwilling to abstain from participating in other clinical trials during the study and for 3 months after receipt of study medication.
- •Participation in another clinical study with DS 1971a.
- •Abnormal ECG waveform morphology at screening that would preclude accurate measurement of the QT interval duration.
- •Corrected QT interval (Fridericia's formula) (QTcF) interval duration > 430 msec, obtained as an average from the measurements on duplicate screening ECGs.
- •Estimated glomerular filtration rate (eGFR) < 80 mL/min/1.73m2 (based on Modification of Diet in Renal Disease [MDRD] equation) or an absolute creatinine value outside the normal range.
- •Use of any prescription or over the counter (OTC) medications, or herbal remedies (such as St John's wort), known to be strong inhibitors or strong inducers of cytochrome (CYP) enzymes (also known as CYP P450 enzymes) during the 30 days before the first dose of study medication; use of any other prescription or OTC medicine (with the exception of acetaminophen (paracetamol)), including dietary supplements or herbal remedies, during the 7 days before the dose of study medication.
- •Consumption of certain foods or beverages before the first dose and throughout the study period.
- •Loss of more than 400 mL blood or donation of blood, plasma, platelets, or any other blood components during the 3 months before the first dose of study medication, or unwilling to abstain from doing so during the study and for 3 months after receipt of study medication.
- •Abuse of drugs or alcohol during the 2 years before the first dose of study medication, or intake of more than 21 units of alcohol weekly.
- •Use of tobacco products or nicotine-containing products during the 3 months before the first dose of study medication and during the study.
- •Evidence of drug or alcohol abuse at screening or admission.
- •Likely possibility that the volunteer will not cooperate with the requirements of the protocol.
- •Objection by GP to the volunteer entering the study.
研究组 & 干预措施
DS-1971a
Experimental
DS-1971a suspension, up to 4650mg/day
干预措施: DS-1971a (Drug)
placebo
Placebo Comparator
matching DS-1971a suspension
干预措施: placebo (Drug)
结局指标
主要结局
adverse events
时间窗: up to 2 months
To assess the safety and tolerability of repeated oral doses of DS-1971a in healthy male subjects the number, severity, and frequency of adverse events will be recorded from enrollment through discharge from study, up to 2 months.
次要结局
- characterise the plasma pharmacokinetics Vss/F (apparent volume of distribution)(Day 1 through Day 17)
- characterise the plasma pharmacokinetics Cmax (maximum concentration)(Day 1 through Day 17)
- characterise the plasma pharmacokinetics CL/F (apparent oral clearance)(Day 1 through Day 17)
- characterise the plasma pharmacokinetics Tmax (time of maximum concentration)(Day 1 through Day 17)
- characterise the plasma pharmacokinetics T½ (terminal half-life)(Day 1 through Day 17)
- characterise the plasma pharmacokinetics AUC (area under curve)(Day 1 through Day 17)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
1 期
Multiple Dose Study of D1971a in Healthy VolunteersHealthyNCT02564861Daiichi Sankyo25
已完成
1 期
A Study to Assess the Safety, Tolerability and Pharmacokinetics of Multiple Subcutaneous Injections of ABBV-257 in Subjects With Rheumatoid ArthritisRheumatoid ArthritisNCT02531178AbbVie8
已完成
1 期
TAK-648 Multiple-Rising Dose Study in Healthy Japanese Participants and Non-Japanese Participants With Type 2 Diabetes MellitusType 2 Diabetes MellitusNCT02430870Takeda48
终止
1 期
A Study of Orally Administered IPG7236 in Healthy Adult ParticipantsAtopic DermatitisNCT05288543Nanjing Immunophage Biotech Co., Ltd63
已完成
1 期
Randomized, Double-Blind, Placebo-Controlled, MAD Study to Assess the Safety, Tolerability, and Pharmacokinetics of SXC 2023Healthy VolunteersNCT03542435Promentis Pharmaceuticals, Inc.40